What is AgaMatrix?
Founded in 2001 and headquartered in Salem, New Hampshire, AgaMatrix specializes in the development, manufacturing, and marketing of advanced diagnostic technologies. The company occupies a critical niche at the intersection of hardware and software, providing sophisticated blood glucose monitoring systems that leverage mobile and cloud-based data management. By bridging the gap between clinical-grade diagnostics and consumer-friendly digital interfaces, AgaMatrix addresses the growing demand for real-time health monitoring and actionable patient data. Their market position is defined by a commitment to precision, user-centric design, and the seamless integration of diagnostic hardware with modern digital health infrastructure.
How much funding has AgaMatrix raised?
AgaMatrix has raised a total of $63.7M across 5 funding rounds:
Series A
$2.7M
Series B
$5M
Series C
$23.7M
Debt
$32M
Debt
$350K
Series A (2003): $2.7M with participation from Tank Partners and Collaborative Fund
Series B (2007): $5M, investors not publicly disclosed
Series C (2008): $23.7M supported by Noble International Ltd
Debt (2017): $32M featuring Prospect Capital Corporation
Debt (2020): $350K backed by PPP
Key Investors in AgaMatrix
Tank Partners
A venture capital firm focused on providing strategic growth capital to early-stage companies within the technology and healthcare sectors.
Collaborative Fund
An investment firm that backs mission-driven founders and companies that are pushing the boundaries of innovation in consumer and enterprise markets.
Noble International Ltd
A leader in patient adherence solutions, Noble develops training devices and pharma services programs to improve the lives of patients through education and human factors engineering.
What's next for AgaMatrix?
Looking ahead, AgaMatrix is positioned to leverage its established diagnostic foundation to further penetrate the digital health market. The recent strategic capital injection provides the necessary liquidity to accelerate research and development initiatives, particularly in the realm of cloud-based analytics and patient adherence technologies. As the healthcare industry shifts toward value-based care models, AgaMatrix's focus on data-driven monitoring tools is likely to become increasingly central to its competitive strategy. Future growth will likely center on expanding its footprint in the global medical device market, enhancing its software-as-a-service capabilities, and deepening partnerships with pharmaceutical and healthcare providers to improve long-term patient health outcomes.
See full AgaMatrix company page
